NeuroMetrix, Inc. (Nasdaq: NURO) today reported that researchers from the University of Rochester School of Medicine and Dentistry will present a scientific poster titled “Wearable TENs band for chemotherapy-induced peripheral neuropathy (CIPN): A feasibility study” at the upcoming annual meeting of the American Pain Society to be held in Pittsburgh, PA, May 17-20.

Chemotherapy-induced peripheral neuropathy (CIPN) is a common cause of chronic neuropathic pain. It is characterized by symptoms that include burning pain, a distorted sense of touch, numbness, tingling, and cramps. CIPN is a common dose limiting side effect of chemotherapy and significantly impacts the quality of life of many cancer survivors. About one-third of patients will develop chronic CIPN 6 months or more after the end of chemotherapy,

The Quell® study was led by Dr. Jennifer Gewandter, Assistant Professor, Department of Anesthesiology. The objective of the study was to test the feasibility of evaluating Quell technology in cancer survivors with CIPN and to obtain preliminary clinical efficacy data.

“We are pleased to have supported this study, and hope it lays the groundwork for a large scale randomized clinical study that further evaluates the efficacy of Quell in CIPN,” said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. “Many Quell users have neuropathic pain, including from CIPN. We therefore hope that this and future studies help us optimize Quell for treatment of chronic neuropathic pain.”

About QuellQuell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.

About NeuroMetrixNeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit NeuroMetrix.com.

NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief Financial Officerneurometrix.ir@neurometrix.com

NeuroMetrix (NASDAQ:NUROW)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025 NeuroMetrix 차트를 더 보려면 여기를 클릭.
NeuroMetrix (NASDAQ:NUROW)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025 NeuroMetrix 차트를 더 보려면 여기를 클릭.